查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2129247

器官晶片材料市場：預測至2034年－全球分析（按材料類型、聚合物類型、水凝膠類型、材料功能、表面修飾、器官模型、組織和生理模型、製造技術、最終用戶和地區分類）

Organ-on-Chip Materials Market Forecasts To 2034 - Global Analysis By Material Type, Polymer Type, Hydrogel Type, Material Function, Surface Modification, Organ Model, Tissue & Physiological Model, Fabrication Technology, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，預計到 2026 年，全球器官晶片材料市場規模將達到 12 億美元，並在預測期內以 28.5% 的複合年成長率成長，到 2034 年將達到 86 億美元。

器官晶片材料市場專注於用於建構能夠忠實模擬人體器官和組織的微觀生理系統的材料。關鍵材料包括聚合物、水凝膠、陶瓷、生物材料和複合材料，這些材料旨在提供適合細胞活動的生物學和機械條件。市場擴張的促進因素包括：人們日益關注減少動物實驗、個人化醫療的重要性日益凸顯，以及微流體和組織工程技術的進步。這些材料擴大應用於藥物研究、藥物篩檢、毒性評估、疾病模擬和治療方案開發。高生物相容性、耐用性和多功能材料的持續研發有望進一步提升器官晶片技術，並擴大其在醫療和生命科學領域的應用。

增加對藥物發現和藥物研發的投資

製藥公司在發現和開發新療法方面的投入不斷增加，推動了對器官晶片材料的需求。製藥公司需要可靠的臨床前模型來評估候選藥物的療效、生物交互作用和毒性，然後再將其推進到人體試驗階段。與傳統的實驗室細胞培養相比，器官晶片平台能夠更真實地模擬特定的人體器官。工程聚合物、薄膜、水凝膠和支架材料等對於建立功能性晶片環境至關重要。製藥公司正日益尋求利用這些技術來降低研發成本、提高研究效率並儘早識別無效的候選化合物。因此，對器官晶片平台的持續投資預計將刺激對特殊材料的需求。

晶片器官材料和研發高成本

高昂的材料成本和研發製程可能會限制晶片器官材料市場的擴張。製造特殊聚合物、水凝膠、薄膜、生物材料和功能塗層通常需要複雜的製造技術和嚴格的品質要求，從而導致成本增加。此外，開發具有合適的生物相容性、機械性能和化學穩定性的材料可能需要大量投資。將這些材料與微流體組件結合併維持受控的測試條件會進一步增加專案成本。小規模的研究預算可能會使小型實驗室、學術機構和新興生技公司難以採用這項技術。因此，材料、製造、測試、檢驗和營運成本的不斷上漲可能會阻礙更廣泛的商業化和應用。

部署到多重器官和複雜的晶片器官系統

互聯多器官晶片平台的發展為先進材料供應商創造了巨大的機會。雖然單一器官模型可以模擬特定的生物功能，但連接多個組織可以更全面地展現系統性的生理交互作用。這些先進平台需要特殊的聚合物、薄膜、水凝膠、支架、塗層以及與微流體結構相容的材料來維持多樣化的組織環境。多重器官系統在藥物分佈、藥物動力學、治療交互作用、疾病機制和系統毒性等方面具有潛在的應用價值。隨著研究日益關注如何模擬複雜的人體生理功能，製造商有機會開發出能夠在整合的「晶片器官」平台中支援多種組織類型的多功能材料。

可重複性和數據可比性的局限性

實驗結果的差異以及跨平台數據比較的困難可能對市場成長構成重大風險。材料、設備設計、細胞群、製造技術、培養環境和分析程序等方面的差異會導致不同研究機構獲得不一致的結果。這種差異使得建立可靠的器官晶片材料和技術評估基準變得更加複雜。此外，平台資訊的保密性限制了資料共用，也使得確定特定材料特性對結果的影響變得困難。除非能夠確保充分的檢驗和可重複性，否則製藥公司和監管機構可能會對採用這些系統持謹慎態度。因此，持續存在的不一致性可能會延緩標準化過程，限制商業化，並減緩對材料的需求成長。

新型冠狀病毒（COVID-19）的影響：

新冠疫情為晶片器官材料市場帶來了短期挑戰和長期成長機會。疫情初期，實驗室關閉、供應鏈中斷、研究活動受限以及與疫情無關的研究項目延期，暫時限制了材料的研發和應用。另一方面，對用於研究SARS-CoV-2感染和評估潛在療法的真實人體模型的需求日益成長，推動了對晶片器官技術的需求。特別是肺晶片系統，在模擬肺部疾病和篩檢候選療法方面展現出極高的應用價值。公共和私人研究經費的增加進一步促進了生物材料和微流體技術的創新。總而言之，疫情提高了市場認知度，並加速了晶片器官材料的未來應用。

在預測期內，聚合物細分市場預計將佔據最大的市場佔有率。

預計在預測期內，聚合物材料將佔據最大的市場佔有率。這主要歸功於晶片器官系統中對聚合物基材料的日益青睞，而聚合物基材料的優勢在於其適應性強、生物相容性好、柔軟性且易於製造。聚合物材料可根據不同晶片設計的需求進行客製化，以實現特定的機械、光學、化學和表面性能。它們廣泛應用於微流體通道、薄膜、支架和結構組件等領域。聚二甲基矽氧烷和熱塑性聚合物能夠製造複雜的微結構，同時支持細胞增殖和可控的流體運動。其加工柔軟性和與先進製造方法的兼容性不斷拓展它們在生物醫學研究和製藥領域的應用。

預計在預測期內，「疾病建模」細分市場將呈現最高的複合年成長率。

在預測期內，「疾病建模」領域預計將呈現最高的成長率，這主要得益於對能夠模擬複雜疾病過程和生理反應的高度相關、先進模型的需求不斷成長。器官晶片系統為研究人員提供了一個可控的環境，使他們能夠模擬與疾病相關的細胞行為、組織間相互作用和生物狀態。患者來源細胞和創新生物材料的日益普及，增強了這些平台模擬疾病特異性特徵的能力。其應用範圍正在擴展到癌症、感染疾病、心血管疾病、神經系統疾病和其他慢性疾病。隨著製藥和生物技術研究人員尋求更具預測性的方法來取代傳統模型，器官晶片技術在疾病研究中的日益普及預計將帶來對專用材料的強勁需求。

市佔率最大的地區：

在預測期內，北美預計將佔據最大的市場佔有率，這主要得益於其成熟的製藥和生物技術產業、先進的醫療保健生態系統以及對尖端生物醫學研究的大量投入。領先的器官晶片（organ-on-chip）開發公司、研究型大學和技術中心的存在，為持續創新和商業化提供了支持。在藥物開發、毒理學、疾病研究和精準醫療領域，擴大使用與人體相關的模型，這推動了對特種材料的需求。支持替代檢測方法的監管措施也正在加速這些方法的普及。此外，產業界、學術界和研究機構之間的合作，正在加速用於器官晶片應用的高級生物材料和微流體技術的開發。

複合年成長率最高的地區：

在預測期內，亞太地區預計將呈現最高的複合年成長率，這主要得益於生物醫學研究的加速發展、製藥業的擴張、醫療基礎設施的完善以及對先進微流體和組織工程技術投資的增加。中國、日本、韓國和印度正透過公共資金、研究計畫以及學術機構與產業界的夥伴關係，不斷提升器官晶片技術的能力。對動物實驗替代方案和更具預測性的人類來源模型的需求日益成長，進一步推動了該技術在全部區域的應用。此外，生技產業的擴張、研究能力的提升以及相對經濟高效的研發環境，也促進了對特種材料投資的增加，從而加速了器官晶片技術在亞太地區的商業化進程。

免費客製化服務：

所有購買此報告的客戶均可享受以下免費自訂選項之一：

  • 企業概況
    • 對其他市場參與者（最多 3 家公司）進行全面分析
    • 對主要公司進行SWOT分析（最多3家公司）
  • 區域細分
    • 根據客戶要求，我們可以提供主要國家的市場估算和預測，以及複合年成長率（註：需經可行性確認）。
  • 競爭性標竿分析
    • 根據產品系列、地理覆蓋範圍和策略聯盟對領先公司進行基準分析。

目錄

第1章執行摘要

  • 市場概覽及主要亮點
  • 促進因素、挑戰與機遇
  • 競爭格局概述
  • 戰略洞察與建議

第2章：研究框架

  • 研究目標和範圍
  • 相關人員分析
  • 研究假設和限制
  • 調查方法

第3章 市場動態與趨勢分析

  • 市場定義與結構
  • 主要市場促進因素
  • 市場限制與挑戰
  • 投資成長機會和重點領域
  • 產業威脅與風險評估
  • 技術與創新展望
  • 新興市場/高成長市場
  • 監管和政策環境
  • 新冠疫情的影響及復甦前景

第4章：競爭環境與策略評估

  • 波特五力分析
    • 供應商的議價能力
    • 買方的議價能力
    • 替代品的威脅
    • 新進入者的威脅
    • 競爭公司之間的競爭
  • 主要公司市佔率分析
  • 產品基準評效和效能比較

第5章：全球晶片器官材料市場：依材料類型分類

  • 聚合物
  • 彈性體
  • 水凝膠
  • 玻璃
  • 矽
  • 金屬
  • 陶瓷
  • 複合材料

第6章：全球晶片器官材料市場：依聚合物類型分類

  • 聚二甲基矽氧烷
  • 聚碳酸酯
  • 聚甲基丙烯酸甲酯
  • 環烯烴共聚物
  • 環烯烴聚合物
  • 聚氨酯
  • 聚乙烯
  • 其他熱塑性聚合物
  • 其他聚合物材料

第7章 全球晶片器官材料市場：以水凝膠類型分類

  • 天然水凝膠
  • 合成水凝膠
  • 混合水凝膠
  • 去細胞細胞外基質水凝膠

第8章：全球晶片器官材料市場：依材料功能分類

  • 結構材料
  • 胞質
  • 模擬細胞外基質的材料
  • 阻隔材料
  • 膜材料
  • 生物活性物質
  • 鷹架材料

第9章：全球晶片器官材料市場：依表面改質分類

  • 電漿治療
  • 化學功能化
  • 蛋白質包覆層
  • 利用胜肽進行功能化
  • 細胞外基質塗層
  • 防污塗層

第10章 全球晶片器官材料市場：依器官模型分類

  • 晶片肝臟
  • 肺晶片
  • 晶片式心臟
  • 晶片上的腎臟
  • 晶片大腦
  • 腸片
  • 晶片上的皮膚
  • 晶片上的胰髒
  • 帶骨尖
  • 晶片上的血管
  • 晶片式生殖器

第11章 全球晶片器官材料市場：依組織和生理模型分類

  • 晶片上的血腦障壁
  • 晶片上的腫瘤
  • 晶片上的血管
  • 晶片上的多重器官
  • 其他組織和生理模型

第12章 全球晶片器官材料市場：依製造技術分類

  • 軟光刻
  • 光刻
  • 3D列印
  • 生物列印
  • 射出成型
  • 雷射微加工
  • 熱壓紋
  • 數控微加工
  • 靜電紡絲

第13章 全球晶片器官材料市場：依應用領域分類

  • 藥物發現和藥物開發
  • 藥物毒性測試
  • 疾病建模
  • 藥物動力學和動態研究
  • 藥物療效測試
  • 個人化醫療
  • 藥物傳輸調查
  • 癌症研究
  • 感染疾病研究”
  • 化妝品和化學物質的安全測試

第14章 全球晶片器官材料市場：依最終用戶分類

  • 製藥和生物技術公司
  • 學術和研究機構
  • 受託研究機構
  • 醫療設備製造商
  • 醫院和臨床研究中心
  • 化妝品和個人護理公司

第15章 全球器官晶片材料市場：依地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 比利時
    • 瑞典
    • 瑞士
    • 波蘭
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 馬來西亞
    • 新加坡
    • 越南
    • 其他亞太國家
  • 南美洲
    • 巴西
    • 阿根廷
    • 哥倫比亞
    • 智利
    • 秘魯
    • 其他南美國家
  • 世界其他地區（RoW）
    • 中東
      • 沙烏地阿拉伯
      • 阿拉伯聯合大公國
      • 卡達
      • 以色列
      • 其他中東國家
    • 非洲
      • 南非
      • 埃及
      • 摩洛哥
      • 其他非洲國家

第16章 策略市場資訊

  • 工業價值網路和供應鏈評估
  • 空白區域和機會地圖
  • 產品演進與市場生命週期分析
  • 通路、經銷商和打入市場策略的評估

第17章 產業趨勢與策略舉措

  • 併購
  • 夥伴關係、聯盟和合資企業
  • 新產品發布和認證
  • 擴大生產能力和投資
  • 其他策略舉措

第18章：公司簡介

  • Emulate, Inc.
  • MIMETAS BV
  • CN Bio Innovations Ltd.
  • TissUse GmbH
  • InSphero AG
  • Nortis, Inc.
  • Hesperos, Inc.
  • AIM Biotech Pte. Ltd.
  • Altis Biosystems
  • Kirkstall Ltd.
  • AlveoliX AG
  • Bi/ond BV
  • BiomimX Srl
  • SynVivo, Inc.
  • BEOnChip
  • Elveflow（Elvesys）
  • BioChip Technologies GmbH
  • Hurel Corporation
Product Code: SMRC39361

According to Stratistics MRC, the Global Organ-on-Chip Materials Market is accounted for $1.2 billion in 2026 and is expected to reach $8.6 billion by 2034 growing at a CAGR of 28.5% during the forecast period. The Organ-on-Chip Materials Market focuses on materials engineered for creating miniature physiological systems that closely mimic human organs and tissues. Key materials include polymers, hydrogels, ceramics, biomaterials, and composite materials designed to provide appropriate biological and mechanical conditions for cellular activity. Market expansion is supported by increasing interest in reducing animal experimentation, the growing importance of personalized healthcare, and technological progress in microfluidics and tissue engineering. These materials are increasingly utilized in pharmaceutical research, drug screening, toxicity assessment, disease simulation, and therapeutic development. Ongoing development of highly biocompatible, durable, and multifunctional materials is expected to improve organ-on-chip technologies and increase their adoption across healthcare and life sciences.

Market Dynamics:

Driver:

Increasing Investment in Drug Discovery and Development

Growing pharmaceutical expenditure on discovering and developing new therapies is strengthening demand for organ-on-chip materials. Drug manufacturers need dependable preclinical testing models for assessing therapeutic performance, biological interactions, and toxicity before advancing candidates into human studies. Organ-on-chip platforms provide more realistic representations of specific human organs compared with conventional laboratory cell cultures. Materials such as engineered polymers, membranes, hydrogels, and scaffolding materials are fundamental to constructing functional chip environments. Pharmaceutical companies seeking to reduce development costs, improve research productivity, and identify ineffective candidates earlier are increasingly exploring these technologies. Consequently, continued investment in organ-on-chip platforms is expected to stimulate demand for specialized materials.

Restraint:

High Cost of Organ-on-Chip Materials and Development

Expensive materials and development processes can restrict the expansion of the Organ-on-Chip Materials Market. Producing specialized polymers, hydrogels, membranes, biomaterials, and functional coatings frequently involves advanced manufacturing methods and strict quality requirements, which raise costs. Considerable investment may also be necessary to develop materials that provide appropriate biological compatibility, mechanical performance, and chemical stability. Combining these materials with microfluidic components and maintaining controlled testing conditions can further increase project expenses. Limited research budgets may make adoption challenging for smaller laboratories, academic institutions, and early-stage biotechnology companies. Therefore, elevated material, manufacturing, testing, validation, and operational expenditures can slow broader commercialization and adoption.

Opportunity:

Expansion into Multi-Organ and Complex Organ-on-Chip Systems

Growing development of interconnected and multi-organ chip platforms creates an important opportunity for advanced material suppliers. While individual organ models can reproduce specific biological functions, linking multiple tissues can provide a more comprehensive representation of whole-body physiological interactions. These sophisticated platforms require specialized polymers, membranes, hydrogels, scaffolds, coatings, and materials compatible with microfluidic architectures to maintain different tissue environments. Multi-organ systems have potential applications in studying drug distribution, pharmacokinetic behavior, interactions between therapies, disease mechanisms, and systemic toxicity. As research increasingly focuses on reproducing complex human physiology, manufacturers have opportunities to create multifunctional materials that can support several tissue types within integrated organ-on-chip platforms.

Threat:

Limited Reproducibility and Data Comparability

Variability in experimental results and difficulty comparing data across platforms can create substantial risks for market growth. Differences in materials, device designs, cell populations, manufacturing techniques, culture environments, and analytical procedures may lead to inconsistent findings between research facilities. This variability complicates efforts to establish reliable benchmarks for evaluating organ-on-chip materials and technologies. Proprietary platform information can also limit data sharing and make it harder to determine the influence of specific material characteristics on outcomes. Without sufficient validation and reproducibility, pharmaceutical companies and regulators may remain cautious about adopting these systems. Continued inconsistency could therefore delay standardization, restrict commercialization, and slow demand for materials

Covid-19 Impact:

The COVID-19 outbreak produced both short-term challenges and long-term growth opportunities for the Organ-on-Chip Materials Market. Early in the pandemic, laboratory shutdowns, supply interruptions, limited research operations, and postponement of non-pandemic studies temporarily constrained material development and utilization. At the same time, the need for realistic human models to study SARS-CoV-2 infections and evaluate potential therapies increased demand for organ-on-chip technologies. Lung-on-chip systems became particularly valuable for reproducing respiratory disease conditions and screening therapeutic candidates. Increased public and private research support further encouraged innovation in biomaterials and microfluidic technologies. Overall, the pandemic strengthened market visibility and accelerated future adoption.

The Polymers segment is expected to be the largest during the forecast period

The Polymers segment is expected to account for the largest market share during the forecast period, driven by the increasing preference for polymer-based materials in organ-on-chip systems because of their adaptable properties, biocompatibility, flexibility, and ease of fabrication. Polymer materials can be customized to achieve specific mechanical, optical, chemical, and surface characteristics required for different chip designs. They are widely applicable in microfluidic channels, membranes, scaffolds, and structural components. Polydimethylsiloxane and thermoplastic polymers enable the production of intricate microstructures while supporting cell growth and controlled fluid movement. Their processing flexibility and compatibility with advanced manufacturing methods continue to expand their use in biomedical research and pharmaceutical applications.

The Disease Modeling segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the Disease Modeling segment is predicted to witness the highest growth rate, driven by rising demand for advanced human-relevant models capable of reproducing complicated disease processes and physiological responses. Organ-on-chip systems provide controlled environments where researchers can simulate disease-related cellular behavior, tissue interactions, and biological conditions. The growing availability of patient-derived cells and innovative biomaterials is improving the ability of these platforms to represent disease-specific characteristics. Applications are expanding across cancer, infectious diseases, cardiovascular disorders, neurological conditions, and other chronic illnesses. As pharmaceutical and biotechnology researchers seek more predictive alternatives to traditional models, increasing adoption of organ-on-chip technologies for disease research is expected to create strong demand for specialized materials.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, driven by the region's well-established pharmaceutical and biotechnology industries, sophisticated healthcare ecosystem, and significant funding for advanced biomedical research. The presence of major organ-on-chip developers, research universities, and technology centers is supporting continuous innovation and commercialization. Growing utilization of human-relevant models for pharmaceutical development, toxicology, disease research, and precision healthcare is strengthening demand for specialized materials. Regulatory initiatives supporting alternative testing approaches are also encouraging adoption. Furthermore, partnerships among industry, academia, and research organizations are accelerating development of advanced biomaterials and microfluidic technologies for organ-on-chip applications.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, driven by accelerating biomedical research, expanding pharmaceutical industries, improving healthcare infrastructure, and growing investments in advanced microfluidic and tissue-engineering technologies. China, Japan, South Korea, and India are increasingly developing organ-on-chip capabilities through public funding, research programs, and partnerships between academic institutions and industry. Demand for alternatives to animal experimentation and more predictive human-based models is further encouraging adoption throughout the region. In addition, expanding biotechnology sectors, growing research capabilities, and comparatively cost-effective development environments are supporting increased investment in specialized materials and accelerating commercialization of organ-on-chip technologies across Asia Pacific.

Key players in the market

Some of the key players in Organ-on-Chip Materials Market include Emulate, Inc., MIMETAS B.V., CN Bio Innovations Ltd., TissUse GmbH, InSphero AG, Nortis, Inc., Hesperos, Inc., AIM Biotech Pte. Ltd., Altis Biosystems, Kirkstall Ltd., AlveoliX AG, Bi/ond B.V., BiomimX S.r.l., SynVivo, Inc., BioChip Technologies GmbH and Hurel Corporation.

Key Developments:

In May 2026, CN Bio joined the NAMs-DC coalition led by the Critical Path Institute as a founding member. The col laboration aims to accelerate validation, qualification, and regulatory adoption of new approach methodologies, including complex in-vitro and organ-on-chip models, while developing more consistent qualification frameworks for defined contexts of use.

In February 2026, InSphero announced a partnership with PharmaNest to advance translational fibrosis research using human-relevant 3D in-vitro models. The collaboration is focused on improving the assessment of fibrosis and supporting more predictive drug-development research.

In January 2026, Hesperos announced a strategic channel sales partnership with AsedaSciences, combining Hesperos' Human-on-a-Chip technology with AsedaSciences' AI-driven 3RnD platform to support more predictive and efficient drug and chemical development.

Material Types Covered:

  • Polymers
  • Elastomers
  • Hydrogels
  • Glass
  • Silicon
  • Metals
  • Ceramics
  • Composite Materials

Polymer Types Covered:

  • Polydimethylsiloxane
  • Polycarbonate
  • Polymethyl Methacrylate
  • Cyclic Olefin Copolymer
  • Cyclic Olefin Polymer
  • Polyurethane
  • Polyethylene
  • Other Thermoplastic Polymers
  • Other Polymer Materials

Hydrogel Types Covered:

  • Natural Hydrogels
  • Synthetic Hydrogels
  • Hybrid Hydrogels
  • Decellularized Extracellular Matrix Hydrogels

Material Functions Covered:

  • Structural Materials
  • Cell-Culture Substrates
  • Extracellular Matrix-Mimicking Materials
  • Barrier Materials
  • Membrane Materials
  • Bioactive Materials
  • Scaffold Materials

Surface Modifications Covered:

  • Plasma Treatment
  • Chemical Functionalization
  • Protein Coating
  • Peptide Functionalization
  • Extracellular Matrix Coating
  • Anti-Fouling Coatings

Organ Models Covered:

  • Liver-on-Chip
  • Lung-on-Chip
  • Heart-on-Chip
  • Kidney-on-Chip
  • Brain-on-Chip
  • Gut-on-Chip
  • Skin-on-Chip
  • Pancreas-on-Chip
  • Bone-on-Chip
  • Vascular-on-Chip
  • Reproductive Organ-on-Chip

Tissue & Physiological Models Covered:

  • Blood-Brain Barrier-on-Chip
  • Tumor-on-Chip
  • Blood Vessel-on-Chip
  • Multi-Organ-on-Chip
  • Other Tissue and Physiological Models

Fabrication Technologies Covered:

  • Soft Lithography
  • Photolithography
  • 3D Printing
  • Bioprinting
  • Injection Molding
  • Laser Micromachining
  • Hot Embossing
  • CNC Micromachining
  • Electrospinning

Applications Covered:

  • Drug Discovery and Development
  • Drug Toxicity Testing
  • Disease Modeling
  • Pharmacokinetic and Pharmacodynamic Studies
  • Drug Efficacy Testing
  • Personalized Medicine
  • Drug Delivery Research
  • Cancer Research
  • Infectious Disease Research
  • Cosmetics and Chemical Safety Testing

End Users Covered:

  • Pharmaceutical and Biotechnology Companies
  • Academic and Research Institutions
  • Contract Research Organizations
  • Medical Device Companies
  • Hospitals and Clinical Research Centers
  • Cosmetics and Personal Care Companies

Regions Covered:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • Netherlands
    • Belgium
    • Sweden
    • Switzerland
    • Poland
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Vietnam
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Argentina
    • Colombia
    • Chile
    • Peru
    • Rest of South America
  • Rest of the World (RoW)
    • Middle East
  • Saudi Arabia
  • United Arab Emirates
  • Qatar
  • Israel
  • Rest of Middle East
    • Africa
  • South Africa
  • Egypt
  • Morocco
  • Rest of Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

  • 1.1 Market Snapshot and Key Highlights
  • 1.2 Growth Drivers, Challenges, and Opportunities
  • 1.3 Competitive Landscape Overview
  • 1.4 Strategic Insights and Recommendations

2 Research Framework

  • 2.1 Study Objectives and Scope
  • 2.2 Stakeholder Analysis
  • 2.3 Research Assumptions and Limitations
  • 2.4 Research Methodology
    • 2.4.1 Data Collection (Primary and Secondary)
    • 2.4.2 Data Modeling and Estimation Techniques
    • 2.4.3 Data Validation and Triangulation
    • 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

  • 3.1 Market Definition and Structure
  • 3.2 Key Market Drivers
  • 3.3 Market Restraints and Challenges
  • 3.4 Growth Opportunities and Investment Hotspots
  • 3.5 Industry Threats and Risk Assessment
  • 3.6 Technology and Innovation Landscape
  • 3.7 Emerging and High-Growth Markets
  • 3.8 Regulatory and Policy Environment
  • 3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

  • 4.1 Porter's Five Forces Analysis
    • 4.1.1 Supplier Bargaining Power
    • 4.1.2 Buyer Bargaining Power
    • 4.1.3 Threat of Substitutes
    • 4.1.4 Threat of New Entrants
    • 4.1.5 Competitive Rivalry
  • 4.2 Market Share Analysis of Key Players
  • 4.3 Product Benchmarking and Performance Comparison

5 Global Organ-on-Chip Materials Market, By Material Type

  • 5.1 Polymers
  • 5.2 Elastomers
  • 5.3 Hydrogels
  • 5.4 Glass
  • 5.5 Silicon
  • 5.6 Metals
  • 5.7 Ceramics
  • 5.8 Composite Materials

6 Global Organ-on-Chip Materials Market, By Polymer Type

  • 6.1 Polydimethylsiloxane
  • 6.2 Polycarbonate
  • 6.3 Polymethyl Methacrylate
  • 6.4 Cyclic Olefin Copolymer
  • 6.5 Cyclic Olefin Polymer
  • 6.6 Polyurethane
  • 6.7 Polyethylene
  • 6.8 Other Thermoplastic Polymers
  • 6.9 Other Polymer Materials

7 Global Organ-on-Chip Materials Market, By Hydrogel Type

  • 7.1 Natural Hydrogels
  • 7.2 Synthetic Hydrogels
  • 7.3 Hybrid Hydrogels
  • 7.4 Decellularized Extracellular Matrix Hydrogels

8 Global Organ-on-Chip Materials Market, By Material Function

  • 8.1 Structural Materials
  • 8.2 Cell-Culture Substrates
  • 8.3 Extracellular Matrix-Mimicking Materials
  • 8.4 Barrier Materials
  • 8.5 Membrane Materials
  • 8.6 Bioactive Materials
  • 8.7 Scaffold Materials

9 Global Organ-on-Chip Materials Market, By Surface Modification

  • 9.1 Plasma Treatment
  • 9.2 Chemical Functionalization
  • 9.3 Protein Coating
  • 9.4 Peptide Functionalization
  • 9.5 Extracellular Matrix Coating
  • 9.6 Anti-Fouling Coatings

10 Global Organ-on-Chip Materials Market, By Organ Model

  • 10.1 Liver-on-Chip
  • 10.2 Lung-on-Chip
  • 10.3 Heart-on-Chip
  • 10.4 Kidney-on-Chip
  • 10.5 Brain-on-Chip
  • 10.6 Gut-on-Chip
  • 10.7 Skin-on-Chip
  • 10.8 Pancreas-on-Chip
  • 10.9 Bone-on-Chip
  • 10.10 Vascular-on-Chip
  • 10.11 Reproductive Organ-on-Chip

11 Global Organ-on-Chip Materials Market, By Tissue & Physiological Model

  • 11.1 Blood-Brain Barrier-on-Chip
  • 11.2 Tumor-on-Chip
  • 11.3 Blood Vessel-on-Chip
  • 11.4 Multi-Organ-on-Chip
  • 11.5 Other Tissue and Physiological Models

12 Global Organ-on-Chip Materials Market, By Fabrication Technology

  • 12.1 Soft Lithography
  • 12.2 Photolithography
  • 12.3 3D Printing
  • 12.4 Bioprinting
  • 12.5 Injection Molding
  • 12.6 Laser Micromachining
  • 12.7 Hot Embossing
  • 12.8 CNC Micromachining
  • 12.9 Electrospinning

13 Global Organ-on-Chip Materials Market, By Application

  • 13.1 Drug Discovery and Development
  • 13.2 Drug Toxicity Testing
  • 13.3 Disease Modeling
  • 13.4 Pharmacokinetic and Pharmacodynamic Studies
  • 13.5 Drug Efficacy Testing
  • 13.6 Personalized Medicine
  • 13.7 Drug Delivery Research
  • 13.8 Cancer Research
  • 13.9 Infectious Disease Research
  • 13.1 Cosmetics and Chemical Safety Testing

14 Global Organ-on-Chip Materials Market, By End User

  • 14.1 Pharmaceutical and Biotechnology Companies
  • 14.2 Academic and Research Institutions
  • 14.3 Contract Research Organizations
  • 14.4 Medical Device Companies
  • 14.5 Hospitals and Clinical Research Centers
  • 14.6 Cosmetics and Personal Care Companies

15 Global Organ-on-Chip Materials Market, By Geography

  • 15.1 North America
    • 15.1.1 United States
    • 15.1.2 Canada
    • 15.1.3 Mexico
  • 15.2 Europe
    • 15.2.1 United Kingdom
    • 15.2.2 Germany
    • 15.2.3 France
    • 15.2.4 Italy
    • 15.2.5 Spain
    • 15.2.6 Netherlands
    • 15.2.7 Belgium
    • 15.2.8 Sweden
    • 15.2.9 Switzerland
    • 15.2.10 Poland
    • 15.2.11 Rest of Europe
  • 15.3 Asia Pacific
    • 15.3.1 China
    • 15.3.2 Japan
    • 15.3.3 India
    • 15.3.4 South Korea
    • 15.3.5 Australia
    • 15.3.6 Indonesia
    • 15.3.7 Thailand
    • 15.3.8 Malaysia
    • 15.3.9 Singapore
    • 15.3.10 Vietnam
    • 15.3.11 Rest of Asia Pacific
  • 15.4 South America
    • 15.4.1 Brazil
    • 15.4.2 Argentina
    • 15.4.3 Colombia
    • 15.4.4 Chile
    • 15.4.5 Peru
    • 15.4.6 Rest of South America
  • 15.5 Rest of the World (RoW)
    • 15.5.1 Middle East
      • 15.5.1.1 Saudi Arabia
      • 15.5.1.2 United Arab Emirates
      • 15.5.1.3 Qatar
      • 15.5.1.4 Israel
      • 15.5.1.5 Rest of Middle East
    • 15.5.2 Africa
      • 15.5.2.1 South Africa
      • 15.5.2.2 Egypt
      • 15.5.2.3 Morocco
      • 15.5.2.4 Rest of Africa

16 Strategic Market Intelligence

  • 16.1 Industry Value Network and Supply Chain Assessment
  • 16.2 White-Space and Opportunity Mapping
  • 16.3 Product Evolution and Market Life Cycle Analysis
  • 16.4 Channel, Distributor, and Go-to-Market Assessment

17 Industry Developments and Strategic Initiatives

  • 17.1 Mergers and Acquisitions
  • 17.2 Partnerships, Alliances, and Joint Ventures
  • 17.3 New Product Launches and Certifications
  • 17.4 Capacity Expansion and Investments
  • 17.5 Other Strategic Initiatives

18 Company Profiles

  • 18.1 Emulate, Inc.
  • 18.2 MIMETAS B.V.
  • 18.3 CN Bio Innovations Ltd.
  • 18.4 TissUse GmbH
  • 18.5 InSphero AG
  • 18.6 Nortis, Inc.
  • 18.7 Hesperos, Inc.
  • 18.8 AIM Biotech Pte. Ltd.
  • 18.9 Altis Biosystems
  • 18.10 Kirkstall Ltd.
  • 18.11 AlveoliX AG
  • 18.12 Bi/ond B.V.
  • 18.13 BiomimX S.r.l.
  • 18.14 SynVivo, Inc.
  • 18.15 BEOnChip
  • 18.16 Elveflow (Elvesys)
  • 18.17 BioChip Technologies GmbH
  • 18.18 Hurel Corporation

List of Tables

  • Table 1 Global Organ-on-Chip Materials Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Organ-on-Chip Materials Market Outlook, By Material Type (2023-2034) ($MN)
  • Table 3 Global Organ-on-Chip Materials Market Outlook, By Polymers (2023-2034) ($MN)
  • Table 4 Global Organ-on-Chip Materials Market Outlook, By Elastomers (2023-2034) ($MN)
  • Table 5 Global Organ-on-Chip Materials Market Outlook, By Hydrogels (2023-2034) ($MN)
  • Table 6 Global Organ-on-Chip Materials Market Outlook, By Glass (2023-2034) ($MN)
  • Table 7 Global Organ-on-Chip Materials Market Outlook, By Silicon (2023-2034) ($MN)
  • Table 8 Global Organ-on-Chip Materials Market Outlook, By Metals (2023-2034) ($MN)
  • Table 9 Global Organ-on-Chip Materials Market Outlook, By Ceramics (2023-2034) ($MN)
  • Table 10 Global Organ-on-Chip Materials Market Outlook, By Composite Materials (2023-2034) ($MN)
  • Table 11 Global Organ-on-Chip Materials Market Outlook, By Polymer Type (2023-2034) ($MN)
  • Table 12 Global Organ-on-Chip Materials Market Outlook, By Polydimethylsiloxane (2023-2034) ($MN)
  • Table 13 Global Organ-on-Chip Materials Market Outlook, By Polycarbonate (2023-2034) ($MN)
  • Table 14 Global Organ-on-Chip Materials Market Outlook, By Polymethyl Methacrylate (2023-2034) ($MN)
  • Table 15 Global Organ-on-Chip Materials Market Outlook, By Cyclic Olefin Copolymer (2023-2034) ($MN)
  • Table 16 Global Organ-on-Chip Materials Market Outlook, By Cyclic Olefin Polymer (2023-2034) ($MN)
  • Table 17 Global Organ-on-Chip Materials Market Outlook, By Polyurethane (2023-2034) ($MN)
  • Table 18 Global Organ-on-Chip Materials Market Outlook, By Polyethylene (2023-2034) ($MN)
  • Table 19 Global Organ-on-Chip Materials Market Outlook, By Other Thermoplastic Polymers (2023-2034) ($MN)
  • Table 20 Global Organ-on-Chip Materials Market Outlook, By Other Polymer Materials (2023-2034) ($MN)
  • Table 21 Global Organ-on-Chip Materials Market Outlook, By Hydrogel Type (2023-2034) ($MN)
  • Table 22 Global Organ-on-Chip Materials Market Outlook, By Natural Hydrogels (2023-2034) ($MN)
  • Table 23 Global Organ-on-Chip Materials Market Outlook, By Synthetic Hydrogels (2023-2034) ($MN)
  • Table 24 Global Organ-on-Chip Materials Market Outlook, By Hybrid Hydrogels (2023-2034) ($MN)
  • Table 25 Global Organ-on-Chip Materials Market Outlook, By Decellularized Extracellular Matrix Hydrogels (2023-2034) ($MN)
  • Table 26 Global Organ-on-Chip Materials Market Outlook, By Material Function (2023-2034) ($MN)
  • Table 27 Global Organ-on-Chip Materials Market Outlook, By Structural Materials (2023-2034) ($MN)
  • Table 28 Global Organ-on-Chip Materials Market Outlook, By Cell-Culture Substrates (2023-2034) ($MN)
  • Table 29 Global Organ-on-Chip Materials Market Outlook, By Extracellular Matrix-Mimicking Materials (2023-2034) ($MN)
  • Table 30 Global Organ-on-Chip Materials Market Outlook, By Barrier Materials (2023-2034) ($MN)
  • Table 31 Global Organ-on-Chip Materials Market Outlook, By Membrane Materials (2023-2034) ($MN)
  • Table 32 Global Organ-on-Chip Materials Market Outlook, By Bioactive Materials (2023-2034) ($MN)
  • Table 33 Global Organ-on-Chip Materials Market Outlook, By Scaffold Materials (2023-2034) ($MN)
  • Table 34 Global Organ-on-Chip Materials Market Outlook, By Surface Modification (2023-2034) ($MN)
  • Table 35 Global Organ-on-Chip Materials Market Outlook, By Plasma Treatment (2023-2034) ($MN)
  • Table 36 Global Organ-on-Chip Materials Market Outlook, By Chemical Functionalization (2023-2034) ($MN)
  • Table 37 Global Organ-on-Chip Materials Market Outlook, By Protein Coating (2023-2034) ($MN)
  • Table 38 Global Organ-on-Chip Materials Market Outlook, By Peptide Functionalization (2023-2034) ($MN)
  • Table 39 Global Organ-on-Chip Materials Market Outlook, By Extracellular Matrix Coating (2023-2034) ($MN)
  • Table 40 Global Organ-on-Chip Materials Market Outlook, By Anti-Fouling Coatings (2023-2034) ($MN)
  • Table 41 Global Organ-on-Chip Materials Market Outlook, By Organ Model (2023-2034) ($MN)
  • Table 42 Global Organ-on-Chip Materials Market Outlook, By Liver-on-Chip (2023-2034) ($MN)
  • Table 43 Global Organ-on-Chip Materials Market Outlook, By Lung-on-Chip (2023-2034) ($MN)
  • Table 44 Global Organ-on-Chip Materials Market Outlook, By Heart-on-Chip (2023-2034) ($MN)
  • Table 45 Global Organ-on-Chip Materials Market Outlook, By Kidney-on-Chip (2023-2034) ($MN)
  • Table 46 Global Organ-on-Chip Materials Market Outlook, By Brain-on-Chip (2023-2034) ($MN)
  • Table 47 Global Organ-on-Chip Materials Market Outlook, By Gut-on-Chip (2023-2034) ($MN)
  • Table 48 Global Organ-on-Chip Materials Market Outlook, By Skin-on-Chip (2023-2034) ($MN)
  • Table 49 Global Organ-on-Chip Materials Market Outlook, By Pancreas-on-Chip (2023-2034) ($MN)
  • Table 50 Global Organ-on-Chip Materials Market Outlook, By Bone-on-Chip (2023-2034) ($MN)
  • Table 51 Global Organ-on-Chip Materials Market Outlook, By Vascular-on-Chip (2023-2034) ($MN)
  • Table 52 Global Organ-on-Chip Materials Market Outlook, By Reproductive Organ-on-Chip (2023-2034) ($MN)
  • Table 53 Global Organ-on-Chip Materials Market Outlook, By Tissue & Physiological Model (2023-2034) ($MN)
  • Table 54 Global Organ-on-Chip Materials Market Outlook, By Blood-Brain Barrier-on-Chip (2023-2034) ($MN)
  • Table 55 Global Organ-on-Chip Materials Market Outlook, By Tumor-on-Chip (2023-2034) ($MN)
  • Table 56 Global Organ-on-Chip Materials Market Outlook, By Blood Vessel-on-Chip (2023-2034) ($MN)
  • Table 57 Global Organ-on-Chip Materials Market Outlook, By Multi-Organ-on-Chip (2023-2034) ($MN)
  • Table 58 Global Organ-on-Chip Materials Market Outlook, By Other Tissue and Physiological Models (2023-2034) ($MN)
  • Table 59 Global Organ-on-Chip Materials Market Outlook, By Fabrication Technology (2023-2034) ($MN)
  • Table 60 Global Organ-on-Chip Materials Market Outlook, By Soft Lithography (2023-2034) ($MN)
  • Table 61 Global Organ-on-Chip Materials Market Outlook, By Photolithography (2023-2034) ($MN)
  • Table 62 Global Organ-on-Chip Materials Market Outlook, By 3D Printing (2023-2034) ($MN)
  • Table 63 Global Organ-on-Chip Materials Market Outlook, By Bioprinting (2023-2034) ($MN)
  • Table 64 Global Organ-on-Chip Materials Market Outlook, By Injection Molding (2023-2034) ($MN)
  • Table 65 Global Organ-on-Chip Materials Market Outlook, By Laser Micromachining (2023-2034) ($MN)
  • Table 66 Global Organ-on-Chip Materials Market Outlook, By Hot Embossing (2023-2034) ($MN)
  • Table 67 Global Organ-on-Chip Materials Market Outlook, By CNC Micromachining (2023-2034) ($MN)
  • Table 68 Global Organ-on-Chip Materials Market Outlook, By Electrospinning (2023-2034) ($MN)
  • Table 69 Global Organ-on-Chip Materials Market Outlook, By Application (2023-2034) ($MN)
  • Table 70 Global Organ-on-Chip Materials Market Outlook, By Drug Discovery and Development (2023-2034) ($MN)
  • Table 71 Global Organ-on-Chip Materials Market Outlook, By Drug Toxicity Testing (2023-2034) ($MN)
  • Table 72 Global Organ-on-Chip Materials Market Outlook, By Disease Modeling (2023-2034) ($MN)
  • Table 73 Global Organ-on-Chip Materials Market Outlook, By Pharmacokinetic and Pharmacodynamic Studies (2023-2034) ($MN)
  • Table 74 Global Organ-on-Chip Materials Market Outlook, By Drug Efficacy Testing (2023-2034) ($MN)
  • Table 75 Global Organ-on-Chip Materials Market Outlook, By Personalized Medicine (2023-2034) ($MN)
  • Table 76 Global Organ-on-Chip Materials Market Outlook, By Drug Delivery Research (2023-2034) ($MN)
  • Table 77 Global Organ-on-Chip Materials Market Outlook, By Cancer Research (2023-2034) ($MN)
  • Table 78 Global Organ-on-Chip Materials Market Outlook, By Infectious Disease Research (2023-2034) ($MN)
  • Table 79 Global Organ-on-Chip Materials Market Outlook, By Cosmetics and Chemical Safety Testing (2023-2034) ($MN)
  • Table 80 Global Organ-on-Chip Materials Market Outlook, By End User (2023-2034) ($MN)
  • Table 81 Global Organ-on-Chip Materials Market Outlook, By Pharmaceutical and Biotechnology Companies (2023-2034) ($MN)
  • Table 82 Global Organ-on-Chip Materials Market Outlook, By Academic and Research Institutions (2023-2034) ($MN)
  • Table 83 Global Organ-on-Chip Materials Market Outlook, By Contract Research Organizations (2023-2034) ($MN)
  • Table 84 Global Organ-on-Chip Materials Market Outlook, By Medical Device Companies (2023-2034) ($MN)
  • Table 85 Global Organ-on-Chip Materials Market Outlook, By Hospitals and Clinical Research Centers (2023-2034) ($MN)
  • Table 86 Global Organ-on-Chip Materials Market Outlook, By Cosmetics and Personal Care Companies (2023-2034) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) Regions are also represented in the same manner as above.